Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Selected Value Therapeutics Acquires China Rights to Cancer Drug

publication date: Jun 8, 2011
Selected Value Therapeutics will acquire the China rights to a cancer drug being developed by US-based EntreMed. The drug, ENMD-2076, has announced efficacy in a Phase II trial conducted among ovarian cancer patients with platinum-drug resistance, a notoriously difficult population without many treatment options. To gain China rights for the drug, Selected Value, a virtual company, is exercising an option it acquired in late 2010, when it invested $5.1 million in a private placement of EntreMed units. More details....

Stock Symbol: (NSDQ: ENMD)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital